Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology

Confirming the Diagnosis: Lab Tests and Imaging

At a Glance

A positive sputum culture does not by itself confirm Aspergillus niger lung infection because the fungus can harmlessly colonize the airways. Doctors combine symptoms and risk factors with chest CT findings and tests such as IgG, galactomannan, PCR, sequencing, or biopsy.

Diagnosing an Aspergillus niger infection in the lungs is a complex puzzle. A single positive result on a lab report—such as a “sputum culture”—is rarely enough to confirm a diagnosis [1][2]. Because this fungus is common in the environment and can live harmlessly in the airways (colonization), doctors integrate evidence from multiple different categories before diagnosing a true infection [3][1].

The Integrated Diagnostic Process

To diagnose a lung infection like Chronic Pulmonary Aspergillosis (CPA) or Invasive Pulmonary Aspergillosis (IPA), clinicians integrate evidence from three areas, though they may diagnose probable disease and begin treatment without obtaining every category:

  1. Clinical Evidence (Your Risks and Symptoms): Clinicians look for a health history that makes an infection likely (such as a weakened immune system or prior lung damage) and symptoms like a persistent cough, fever, or weight loss [3][4].
  2. Radiological Evidence (Imaging): A Chest CT scan may show physical changes in the lung, such as a “fungal ball” inside a cavity, new nodules, or specific signs of tissue invasion [3][5].
  3. Mycological Evidence (Lab Tests): This involves finding supporting evidence of the fungus through cultures, blood tests, or specialized molecular markers [6][3].

Why Culture is Often Not Enough

A sputum culture (where you cough into a cup) simply tells the doctor that the fungus was present in your airway at that moment. It cannot distinguish between a harmless “visitor” and a dangerous invader [1][7]. In one study, many patients with a positive Aspergillus sample were actually colonized and did not have an active disease [8].

Furthermore, A. niger is part of a group called the “black Aspergilli.” Under a standard microscope, many different species look identical [9]. What is labeled as “A. niger” on your report might actually be a “cryptic species” like A. tubingensis, which can have variable responses to standard antifungal drugs [10][11]. For a definitive identification in invasive or refractory disease, doctors may use molecular sequencing (analyzing the fungus’s DNA) or MALDI-TOF (analyzing its protein profile) [12][13].

Specialized Laboratory Tests

When a simple culture isn’t enough, your doctor may order these more advanced tests:

Aspergillus-Specific IgG (The Antibody Test)

This blood test looks for the immune system’s response to the fungus. It is a cornerstone for diagnosing chronic infections (CPA) [3].

  • The “Non-Fumigatus” Problem: Most clinical CPA workups use a validated Aspergillus IgG assay with variable cross-reactivity [14]. A negative result does not by itself exclude CPA, and species-specific assays are not uniformly available or required [15].

Galactomannan (GM)

Galactomannan is a molecule found in the cell walls of the fungus. When the fungus is actively growing and invading tissue, this molecule “leaks” into the blood or lung fluid [16].

  • Serum vs. BAL: Testing for GM in the blood (serum) is sometimes used, but it is less sensitive in many non-neutropenic patients and in CPA. Testing the fluid directly from your lungs during a bronchoscopy (called BAL galactomannan) is an adjunct, but it can be positive with airway colonization and is not specific by itself [17][18].

PCR (DNA Testing)

Aspergillus PCR (Polymerase Chain Reaction) is a highly sensitive test that searches for small fragments of fungal DNA in your blood or lung fluid [19]. It can find the fungus even when a culture fails to grow anything, but its performance depends on the assay and specimen, and it can sometimes be positive even in people who are only colonized [20][21].

Tissue Biopsy

A tissue biopsy can establish tissue invasion, where a specialist removes a tiny piece of lung tissue and looks at it under a microscope to confirm a “proven” infection [6][7]. However, a biopsy is invasive and often unnecessary when probable IPA is treated clinically; it is not appropriate to imply that every patient should pursue a biopsy [6].

Test Type What it Detects Best For
Culture Living fungus in a sample Basic identification; susceptibility testing [1]
IgG Antibody Your immune response Chronic infections (CPA) [3]
Galactomannan Fungal cell wall “leakage” Invasive infections (IPA) [16]
PCR Fungal DNA fragments Rapid, highly sensitive detection [19]
Sequencing Exact genetic identity Distinguishing A. niger from “cryptic” species [12]
Biopsy Physical invasion of tissue Confirming a “proven” infection [6]

Common questions in this guide

Does a positive sputum culture mean I definitely have an Aspergillus niger lung infection?
Not necessarily. A sputum culture shows that Aspergillus was present in the airway, but it cannot reliably tell harmless colonization from active infection. Doctors interpret it alongside symptoms, risk factors, chest CT findings, and other tests.
What can a negative Aspergillus IgG test tell me?
A negative Aspergillus IgG result does not by itself rule out chronic pulmonary aspergillosis. Assays can respond differently to species other than A. fumigatus, and your clinician will interpret the result with your symptoms, imaging, and other laboratory findings.
Why might my report need sequencing after it says Aspergillus niger?
Several black Aspergillus species look alike under a standard microscope, so a label of A. niger may not identify the exact species. Molecular sequencing or MALDI-TOF can provide a more specific identification, which may matter because related species can respond differently to antifungal medicines.
What might a chest CT show when Aspergillus infection is active?
A CT may show a fungal ball in a pre-existing cavity, new nodules, or changes suggesting tissue invasion. These findings are not interpreted alone; clinicians combine them with your symptoms, health history, and fungus-related test results.
Would a bronchoscopy make the diagnosis more certain than a sputum test?
Bronchoscopy can collect fluid from a specific area of the lungs for galactomannan or PCR testing, and this may add information beyond sputum. However, either test can be positive when the fungus is only colonizing the airways, so a result is not conclusive by itself. Your clinician weighs the possible benefit against the procedure's risks.
Can the laboratory test whether antifungal medicines will work?
If a culture grows the fungus, the laboratory may be able to perform antifungal susceptibility testing. This can help guide medication choices, particularly when disease does not respond as expected, but it does not by itself prove that colonization is an active infection.
Is a lung biopsy always needed to diagnose Aspergillus infection?
No. A biopsy can prove that the fungus has invaded lung tissue, but it is invasive and often unnecessary when clinicians diagnose and treat probable invasive pulmonary aspergillosis using the overall clinical picture. Your care team decides whether its potential benefit outweighs its risks.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Aspergillus niger infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since the report says 'Aspergillus niger,' was this ID confirmed by molecular sequencing, or just by how it looks under a microscope?
  2. 2.My Aspergillus IgG test was negative—could it be that we need a test specifically for 'non-fumigatus' species or A. niger?
  3. 3.Does my recent CT scan show the 'cavities' or 'nodules' that would be expected if this were a true infection like CPA?
  4. 4.Would a bronchoscopy for a 'BAL galactomannan' or 'PCR' test provide more certainty than my current sputum samples?
  5. 5.Since we found the fungus, can we run an antifungal susceptibility test to see if standard medications will actually work on this specific strain?

References

References (21)
  1. 1

    The clinical significance of Aspergillus-positive respiratory samples.

    Katriina P, Veli-Jukka A, Ulla H

    Mycoses 2023; (66(5)):387-395 doi:10.1111/myc.13566.

    PMID: 36654511
  2. 2

    Diagnostic Laboratory Features and Performance of an Aspergillus IgG Lateral Flow Assay in a Chronic Pulmonary Aspergillosis Cohort.

    Zhu RS, Zhou LH, Cheng JH, et al.

    Microbiology spectrum 2023; (11(3)):e0026423 doi:10.1128/spectrum.00264-23.

    PMID: 37125929
  3. 3

    Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.

    Denning DW, Cadranel J, Beigelman-Aubry C, et al.

    The European respiratory journal 2016; (47(1)):45-68 doi:10.1183/13993003.00583-2015.

    PMID: 26699723
  4. 4

    Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

    Denning DW, Rogers TR, Takazono T, et al.

    American journal of respiratory and critical care medicine 2026; doi:10.1093/ajrccm/aamag310.

    PMID: 42384914
  5. 5

    Epidemiological characteristics of patients with invasive pulmonary aspergillosis infected with Aspergillus fumigatus from a tertiary hospital in Ningxia, China.

    Kang Y, Li Q, Ma W, et al.

    Scientific reports 2025; (15(1)):13036 doi:10.1038/s41598-025-97587-y.

    PMID: 40234690
  6. 6

    Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.

    Verweij PE, Rijnders BJA, Brüggemann RJM, et al.

    Intensive care medicine 2020; (46(8)):1524-1535 doi:10.1007/s00134-020-06091-6.

    PMID: 32572532
  7. 7

    [Aspergillus in airway material : Ignore or treat?]

    Salzer HJF, Lange C, Hönigl M

    Der Internist 2017; (58(11)):1150-1162 doi:10.1007/s00108-017-0334-9.

    PMID: 28986661
  8. 8

    Clinical characteristics of patients with Aspergillus species isolation from respiratory samples: Comparison of chronic pulmonary aspergillosis and colonization.

    Ohara S, Tazawa Y, Tanai C, et al.

    Respiratory investigation 2016; (54(2)):92-7.

    PMID: 26879478
  9. 9

    The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan.

    Hagiwara S, Tamura T, Satoh K, et al.

    Mycopathologia 2019; (184(1)):13-21 doi:10.1007/s11046-018-0299-9.

    PMID: 30291485
  10. 10

    The accuracy and clinical impact of the morphological identification of Aspergillus species in the age of cryptic species: A single-centre study.

    Takeda K, Suzuki J, Watanabe A, et al.

    Mycoses 2022; (65(2)):164-170 doi:10.1111/myc.13397.

    PMID: 34783396
  11. 11

    Importance of Accurate Identification and Antifungal Susceptibility Testing of Aspergillus Species in Clinical Settings.

    Takeda K, Suzuki J, Sasaki Y, et al.

    Medical mycology journal 2023; (64(4)):95-98 doi:10.3314/mmj.23-004.

    PMID: 38030277
  12. 12

    Molecular Analysis for Potential Hospital-Acquired Infection Caused by Aspergillus Tubingensis Through the Environment.

    Tanamachi C, Iwahashi J, Togo A, et al.

    The Kurume medical journal 2024; (69(3.4)):185-193 doi:10.2739/kurumemedj.MS6934013.

    PMID: 38233176
  13. 13

    Diversity within Aspergillus niger Clade and Description of a New Species: Aspergillus vinaceus sp. nov.

    Silva JJD, Iamanaka BT, Ferranti LS, et al.

    Journal of fungi (Basel, Switzerland) 2020; (6(4)) doi:10.3390/jof6040371.

    PMID: 33348541
  14. 14

    Improving Diagnostic Sensitivity of Chronic Pulmonary Aspergillosis Using Species-Specific IgG.

    Sehgal IS, Agarwal R, Muthu V, et al.

    Mycoses 2025; (68(9)):e70107 doi:10.1111/myc.70107.

    PMID: 40899055
  15. 15

    Clinical applications of immunoglobulin G against different individual Aspergillus species for the diagnosis of chronic pulmonary aspergillosis among at-risk populations.

    Keng LT, Lin CC, Wu CW, et al.

    Pathogens and global health 2024; (118(7-8)):574-581 doi:10.1080/20477724.2024.2424489.

    PMID: 39504999
  16. 16

    Serology anno 2021-fungal infections: from invasive to chronic.

    Lass-Flörl C, Samardzic E, Knoll M

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2021; (27(9)):1230-1241 doi:10.1016/j.cmi.2021.02.005.

    PMID: 33601011
  17. 17

    Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline.

    Hage CA, Carmona EM, Epelbaum O, et al.

    American journal of respiratory and critical care medicine 2019; (200(5)):535-550 doi:10.1164/rccm.201906-1185ST.

    PMID: 31469325
  18. 18

    Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff.

    de Oliveira VF, Silva GD, Taborda M, et al.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2023; (42(9)):1047-1054 doi:10.1007/s10096-023-04639-0.

    PMID: 37430166
  19. 19

    Detection of Aspergillus DNA in BALF by Real-time PCR and Galactomannan Antigen for the Early Diagnosis of Chronic Pulmonary Aspergillosis.

    Ye F, Zeng P, Li Z, et al.

    Annals of clinical and laboratory science 2021; (51(5)):698-704.

    PMID: 34686513
  20. 20

    Usefulness of Two Aspergillus PCR Assays and Aspergillus Galactomannan and β-d-Glucan Testing of Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.

    Urabe N, Sakamoto S, Sano G, et al.

    Journal of clinical microbiology 2017; (55(6)):1738-1746 doi:10.1128/JCM.02497-16.

    PMID: 28330887
  21. 21

    Direct Molecular Diagnosis of Aspergillosis and CYP51A Profiling from Respiratory Samples of French Patients.

    Zhao Y, Garnaud C, Brenier-Pinchart MP, et al.

    Frontiers in microbiology 2016; (7()):1164 doi:10.3389/fmicb.2016.01164.

    PMID: 27524978

This page explains how clinicians evaluate possible Aspergillus niger lung infection for informational purposes only and does not constitute medical advice. Ask your respiratory or infectious-disease clinician how your results should be interpreted.